Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Gilead Sciences Inc GILD

Healthcare Drug Manufacturers - Major
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic... see more

Recent & Breaking News (NDAQ:GILD)

Gilead to Present Latest Research Across Key Liver Disease Indication at the American Association for the Study of Liver Disease (AASLD) Meeting 2024

Business Wire October 22, 2024

Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48

Business Wire October 19, 2024

Gilead Sciences to Release Third Quarter 2024 Financial Results on Wednesday, November 6, 2024

Business Wire October 9, 2024

Gilead to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024

Business Wire October 9, 2024

Gilead Sciences: New Report Shows Every Country in the World Must Do More To End the HIV Epidemic

ACCESS Newswire October 8, 2024

Gilead Presents Additional Efficacy, Safety and Demographic Data From PURPOSE 2 Trial at 5th HIV Research for Prevention Conference

Business Wire October 7, 2024

Hetero Signs Voluntary Licensing Agreement with Gilead to Transform Global HIV response, Expanding Access to Groundbreaking Lenacapavir to 120 high-incidence countries

PR Newswire October 2, 2024

Gilead Signs Royalty-Free Voluntary Licensing Agreements With Six Generic Manufacturers to Increase Access to Lenacapavir for HIV Prevention in High-Incidence, Resource-Limited Countries

Business Wire October 2, 2024

Championing HIV Services for LGBTQ+ Youth

ACCESS Newswire September 25, 2024

Working to Build Next-Generation Cancer Therapies

ACCESS Newswire September 18, 2024

Helping End HIV - Gilead Sciences

ACCESS Newswire September 12, 2024

Gilead's Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV Infections by 96% and Demonstrated Superiority to Daily Truvada® in Second Pivotal Phase 3 Trial

Business Wire September 12, 2024

Seramount Ranks Gilead Sciences Among Its Leading Inclusion Index Company

ACCESS Newswire September 10, 2024

Gilead and Genesis Therapeutics Announce Strategic Collaboration to Discover and Develop Novel Therapies

Business Wire September 10, 2024

Gilead Sciences: Living With a Rare Liver Disease: Maria's Journey

ACCESS Newswire September 6, 2024

Gilead to Present New Trodelvy® Data at the IASLC 2024 World Conference on Lung Cancer

Business Wire September 5, 2024

Gilead Sciences: Innovative Approaches to Healthcare Can Remove Barriers

ACCESS Newswire September 4, 2024

"The Adventure Jar," Showcases a Family Navigating the Challenges of a Cancer Diagnosis and Finding Magic in Time Together

ACCESS Newswire August 27, 2024

Gilead Sciences to Present at Upcoming Investor Conferences

Business Wire August 21, 2024

Gilead Sciences: "One of Best Employers for Women" by Forbes

ACCESS Newswire August 20, 2024

Podcasts